On a jour­ney to find and fu­el new biotech ven­tures, Ar­ix adds France's Ipsen to its net­work of part­ners

Ar­ix Bio­science is clear­ly in a deal-mak­ing mood, strik­ing a new col­lab­o­ra­tion with France’s Ipsen (Eu­ronext: $IPN) just a day af­ter an­nounc­ing a part­ner­ship with Fo­s­un in Chi­na.

To­day’s agree­ment, like Ar­ix’s pre­vi­ous ones, is paint­ed in broad strokes. With a goal to de­vel­op and com­mer­cial­ize in­no­v­a­tive ther­a­pies, Ar­ix (LSE: $AR­IX) of­fers ac­cess to its net­work of ad­vis­ers and the chance to in­vest in its busi­ness­es in ex­change for Ipsen’s R&D and com­mer­cial ex­per­tise. To­geth­er, the part­ners will iden­ti­fy op­por­tu­ni­ties to cre­ate joint ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER